# Strados Labs

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/strados-labs

- Industry: Medical Devices & Equipment
- Headquarters: Philadelphia, US
- Website: www.stradoslabs.com
- Total disclosed funding: $4.3M
- Latest round: Series A (Jul 22, 2021)
- Investors on record: 4

## About

Strados Labs, Inc. is a healthcare technology company specializing in remote monitoring solutions for respiratory health, utilizing innovative wearable biosensor technology to enhance patient care and clinical research.Founded in 2016 and headquartered in Philadelphia, US, Strados Labs, Inc. focuses on developing solutions for continuous monitoring of lung sounds. The company raised USD 1.21 mn in a funding round on November 5, 2021, with participation from Blu Venture Investors, SOSV, and Wavemaker Three-Sixty Health. The founders, Nick Delmonico and Richard Powers, have a background in healthcare and technology innovations, though specific prior ventures are not mentioned.Strados Labs' core product, the RESP® Biosensor, is a wearable device designed for the continuous, passive monitoring of lung sounds, including cough, wheeze, and crackles. It is the first FDA-cleared device allowing for remote patient monitoring, providing insights into respiratory health from patients' homes. This technology connects to a proprietary cloud platform for secure data collection and processing, aiming to prevent unnecessary hospitalizations. Strados Labs serves healthcare systems, life sciences organizations, and patients with chronic respiratory diseases like COPD and asthma, with the RESP® Biosensor deployed across four continents and available in 35 languages.Strados Labs operates a business model that involves partnerships with healthcare providers and life sciences organizations, focusing on delivering the RESP® Biosensor for inpatient and outpatient settings. Revenue generation includes subscription-based services for continuous monitoring, as well as direct-to-consumer sales for patients needing remote health management, accommodating various stakeholders engaged in respiratory health research.Following the USD 1.21 mn funding round in November 2021, Strados Labs plans to scale the RESP® Biosensor, conduct decentralized clinical trials, and enhance their proprietary lung sound and breathing pattern database to establish standards for acoustic biomarkers. The company aims to expand its market presence in North America and Europe by 2023, launching new products designed to improve respiratory monitoring and health outcomes.

## Funding rounds

- Series A, Jul 22, 2021, $1.9M — SOSV
- Seed, Apr 24, 2019, $1.9M — SOSV, HAX
- Seed, Oct 9, 2018, $0.5M — Ben Franklin Technology Partners, SOSV, HAX, Cathexis Investment Management

## Investors

- Ben Franklin Technology Partners (https://capitalatlas.ai/funds/ben-franklin-technology-partners) — Seed
- SOSV (https://capitalatlas.ai/funds/sosv) — Seed, Series A
- HAX — Seed
- Cathexis Investment Management (https://capitalatlas.ai/funds/cathexis-investment-management) — Seed